



Vista Pharmaceuticals Ltd

CIN : L24239TG1991PLC012264
Plot No. 104, Ravindra Co Operative Society, Guttala Begumpet,
Kakateeya Hills, Hyderabad - 500 081. Telangana, INDIA. Tel : 040 - 23741585
E-mail : admin.hyd@vistapharmaceuticals.com @www.vistapharmaceuticals.com

To,
BSE Limited,
P.J. Towers, Dalal Street,
Mumbai - 400001

Date: 13.11.2025

Dear Sir/Madam,

Sub: Outcome of board meeting under regulations 30 read with 33 (3) of SEBI (Listing Obligations and Disclosure requirements) regulations, 2015

Unit: Vista Pharmaceuticals Limited (BE Scrip Code: 524711)

With reference to the subject cited, this is to inform the Exchange that at the Board meeting of M/s. Vista Pharmaceuticals Limited held on Thursday, the 13th day of November, 2025 at 3.00 P.M. at the registered office of the Company following were duly considered and approved by the Board:



1. Unaudited Financial results together for the quarter and half year ended 30.09.2025 (enclosed).
2. Limited Review Report for the quarter and half year ended 30.09.2025 (enclosed).

The meeting of the Board of Directors commenced at 3.00 P.M.(IST) and concluded at 3.45 P.M. (IST)

This is for the information and records of the Exchange, please.

Thanking you.

Yours faithfully,
For Vista Pharmaceuticals Limited

Dhananjaya Alli
Whole time Director
(DIN: 00610909)



Vista Pharmaceuticals Ltd

CIN : L24239TG1991PLC012264
Plot No. 104, Ravindra Co Operative Society, Guttala Begumpet,
Kakateeya Hills, Hyderabad - 500 081. Telangana, INDIA. Tel : 040 - 23741585
E-mail : admin.hyd@vistapharmaceuticals.com @www.vistapharmaceuticals.com

VISTA PHARMACEUTICALS LIMITED							
CIN:L24239TG1991PLC012264							
Statement of Unaudited Financial Results for the Quarter and Half Year ended 30th September,2025							
(in Rs Lakhs)							
S.No	Particulars	Quarter ended			Half- Year ended		Year ended
		September 30,2025	June 30,2025	September 30,2024	September 30,2025	September 30,2024	March 31,2025
		Un Audited	Un Audited	Un Audited	Un Audited	Un Audited	Audited
1	Income						
	a. Revenue from operations	146.25	151.88	249.46	298.13	428.96	1007.46
2	b. Other income	19.24	-	0.70	19.24	7.81	44.06
	Total Income (a+b)	165.49	151.88	250.17	317.37	436.78	1051.52
3	Expenses						
	a) Cost of Material Consumed	146.32	149.84	155.35	296.16	315.62	789.82
	b) Change in Inventories	(0.00)	-	-	0.00	0.00	44.78
	c) Employee benefits expense	56.80	54.25	47.87	111.05	92.84	200.39
	d) Finance costs	17.78	19.31	25.26	37.09	53.51	96.40
	e) Depreciation and amortization expense	19.87	17.58	18.34	37.45	36.66	73.81
	f) Other expenses	286.93	58.90	128.56	345.82	180.49	375.30
	g) Prior Period Expenses	-	-	-	0.00	-	0.00
	Total Expenses	527.70	299.88	375.37	827.58	679.11	1,580.51
4	Profit before tax (2-3)	(362.21)	(148.01)	(125.20)	(510.21)	-242.33	-528.98
5	Tax expense						
	(1) Current tax	0.00	0.00	-	0.00	0.00	0.00
	(2) Deferred tax	(103.35)	(18.97)	(27.83)	-122.32	(59.26)	(107.12)
	(3) Previous year Income tax adjustment	-	0.00	-	0.00	-	43.01
6	Net Profit for the Period (4-5) Other	(258.85)	(129.04)	(97.37)	(387.89)	(183.07)	(464.87)
7	comprehensive income (OCI)						
	(a) (i) Items that will not be reclassified to profit or loss	0.58	1.47	0.00	2.05	0.41	2.11
	(ii) Tax on items that will not be reclassified to profit or loss	-	-	-	-	-	-
	(b) (i) Items that will be reclassified to profit or loss	-	-	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-
8	Total Other Comprehensive income	0.58	1.47	0.00	2.05	0.41	2.11
	Total Comprehensive income (6+7)	(258.28)	(127.57)	(97.36)	(385.85)	(182.66)	(462.76)
Earnings per equity share (Face value of Rs.2/- each)							
	(1) Basic	(0.42)	(0.22)	(0.16)	(0.66)	(0.31)	(0.79)
	(2) Diluted	(0.44)	(0.22)	(0.17)	(0.66)	(0.31)	(0.79)
	Paid- up equity share capital(Face Value of Rs.2/- each)	1,231.04	1,231.04	1,231.04	1,231.04	1,231.04	1,231.04
The accompanying Significant accounting policies and notes form an integral part of the Standalone financial statements.							

For Vista Pharmaceuticals Limited

Dhananjaya



Dhananjaya Alli
Whole Time Director
DIN: 00610909

Date: 13.11.2025
Place: Hyderabad



Vista Pharmaceuticals Ltd

CIN : L24239TG1991PLC012264
Plot No. 104, Ravindra Co Operative Society, Guttala Begumpet,
Kakateeya Hills, Hyderabad - 500 081. Telangana, INDIA. Tel : 040 - 23741585
E-mail : admin.hyd@vistapharmaceuticals.com @www.vistapharmaceuticals.com

Notes:

"1. The financial results of the company have been prepared in accordance with Indian Accounting Standards (Ind AS) notified under the companies (Indian Accounting standards) Rules, 2015 as amended by the companies (Indian Accounting standards) (Amendment) rules, 2016.

2. The above Financial results recommended by the Audit Committee are considered and approved by the Board of Directors at their meeting held on 13th November, 2025

3. The Statutory Auditors of the Company have carried out "Limited Review" of the above unaudited financial results and their Report has been placed before the Board at the said Meeting as required under Regulation 33 of SEBI (LODR) Regulations, 2015.

4. Total Revenue for the current quarter reported Rs 165.49 Lakhs compared to Rs. 250.17 for the corresponding quarter of the previous year.

5. The Loss before tax for the current quarter is Rs.362.21 Lakhs compared to Loss Before tax of Rs. 125.20 Lakhs for the corresponding quarter of the previous year.

6. In the second quarter, the Company has recognized a provision for Expected Credit Loss (ECL) amounting to INR 205.43 lakhs against its long-pending trade receivables. This provision has been made in accordance with the requirements of Ind AS 109 - Financial Instruments, reflecting management's best estimate of the credit losses expected on receivables that have been outstanding for an extended period.

7. During the second quarter, the Company has issued 10,249,998 Convertible Share Warrants and has received 25% of the upfront subscription amounting to INR 307.50 lakhs as part payment. The balance subscription money shall be received as per the terms of the issue.

8. The Entire operations of the Company relate to only one segment i.e Manufacturing of Pharmaceutical Products., Hence, segmental reporting as per IND AS-108 is not made.

9. The results for the quarter ended 30th September 2025 are also available on the bomabay stock exchange website, the National Stock exchange website and on the Company's website.

10. Figures for the previous periods /year have been regrouped/reclassified wherever necessary.

For Vista Pharmaceuticals Limited



Dhananjaya Alli
Whole Time Director
DIN: 00610909

Date: 13.11.2025

Place: Hyderabad



Vista Pharmaceuticals Ltd

CIN : L24239TG1991PLC012264
Plot No. 104, Ravindra Co Operative Society, Guttala Begumpet,
Kakateeya Hills, Hyderabad - 500 081. Telangana, INDIA. Tel : 040 - 23741585
E-mail : admin.hyd@vistapharmaceuticals.com @www.vistapharmaceuticals.com

VISTA PHARMACEUTICALS LIMITED

CIN:L24239TG1991PLC012264

STATEMENT OF ASSETS AND LIABILITIES AS AT 30/09/2025

(Rs. In lakhs)				
S No	Particulars	Note No.	As at 30th Sep 2025 (Unaudited)	As at 31st March 2025 (Audited)
I.	ASSETS			
	Non-current assets			
(a)	Property, Plant and Equipment	2.1	908.15	915.07
(b)	Capital work-in-progress	2.2 (a)	1,055.34	1,013.53
(c)	Intangible assets	2.2 (b)	955.30	955.30
(d)	Financial Assets			
	(i) Investments	2.3	7.30	4.54
	(ii) Other Financial Assets	2.4	13.74	13.74
	(iii) Trade Receivables	2.7	820.39	1,015.16
(e)	Deferred tax assets (Net)	2.12	558.88	437.28
(f)	Other Non-Current Assets	2.5	198.50	198.50
	Total Non - Current Assets		4,517.61	4,553.13
	Current assets			
(a)	Inventories	2.6	761.48	822.01
(b)	Financial assets			-
	(i) Investments			-
	(ii) Trade receivables	2.7	413.03	339.28
	(iii) Cash and Bank equivalents	2.8	13.26	73.33
(c)	Other current assets	2.5	390.52	241.20
	Total Current Assets		1,578.30	1,475.82
	Total Assets		6,095.91	6,028.95



Vista Pharmaceuticals Ltd

CIN : L24239TG1991PLC012264
Plot No. 104, Ravindra Co Operative Society, Guttala Begumpet,
Kakateeya Hills, Hyderabad - 500 081. Telangana, INDIA. Tel : 040 - 23741585
E-mail : admin.hyd@vistapharmaceuticals.com @www.vistapharmaceuticals.com

II	EQUITY AND LIABILITIES			
	Equity			
(a)	Equity Share capital	2.9	1,231.04	1,231.04
(b)	Other equity	2.10	3,232.87	3,311.22
	Total Equity		4,463.91	4,542.25
	Liabilities			
	Non-current liabilities			
(a)	Financial Liabilities			
	(i) Borrowings	2.11	226.04	237.97
	(ii) Other financial liabilities			-
(b)	Deferred tax liabilities (Net)			-
(c)	Provisions	2.15	12.72	12.14
	Total Non - Current Liabilities		238.76	250.11
	Current liabilities			
(a)	Financial Liabilities			
	(i) Borrowings	2.11	624.15	502.47
	(ii) Trade payables	2.13		
	-Total outstanding dues of micro enterprises and small enterprises		5.84	5.71
	-Total outstanding dues of Creditors other than micro enterprises and small enterprises		582.56	553.78
	(iii) Other financial liabilities	2.14	-	-
(b)	Income tax liabilities (net)			-
(c)	Provisions	2.15	3.03	0.58
(d)	Other Current Tax Liabilities	2.16	177.66	174.04
	Total Current Liabilities		1,393.23	1,236.58
	Total Equity and Liabilities		6,095.90	6,028.94

The accompanying Significant accounting policies and notes form an integral part of the Standalone financial statements
For Vista Pharmaceuticals Limited

Dhananjay



Date: 13.11.2025
Place: Hyderabad

Dhananjay Alli
Whole Time Director
DIN: 00610909



Vista Pharmaceuticals Ltd

CIN : L24239TG1991PLC012264
Plot No. 104, Ravindra Co Operative Society, Guttala Begumpet,
Kakateeya Hills, Hyderabad - 500 081. Telangana, INDIA. Tel : 040 - 23741585
E-mail : admin.hyd@vistapharmaceuticals.com @www.vistapharmaceuticals.com

VISTA PHARMACEUTICALS LIMITED Registered Office : Gopalaipalli(Village),Narketpalli(Mandal),Nalgonda Dist.T.S. - 508254 (CIN: L24239TG1991PLC012264) STANDALONE CASH FLOW STATEMENT FOR THE PERIOD ENDED 30TH SEPTEMBER, 2025 (Rs.in Lakhs)		
Particulars	Sep 2025	March 2025
Cash Flows from Operating Activities		
Net profit before tax	(510.21)	(528.98)
Adjustments for :		
Depreciation and amortization expense	37.45	73.81
Gain on investments carried at fair value through profit or loss Gain or	2.77	2.47
Loss on Defined Benefit Plans	0.00	0.38
Interest & Finance Charges Paid Operating profit	37.09	96.40
before working capital changes Movements in Working Capital	(432.90)	(355.92)
(Increase)/Decrease in Inventories (Increase)/Decrease in	60.54	(143.40)
Other financial assets (Increase)/Decrease in Trade	(2.77)	(3.06)
Receivables (Increase)/Decrease in Other Current Assets	121.02	73.69
(Increase)/Decrease in Other Non Current Assets	(149.33)	(17.81)
Increase/(Decrease) in Trade Payables Increase/(Decrease) in	0.00	0.00
Other financial liabilities Increase/(Decrease) in Other	28.91	(181.04)
Current liabilities Increase/(Decrease) in Other Non Current	0.00	(5.30)
liabilities Increase/(Decrease) in Provisions	3.62	(26.17)
Changes in Working Capital	0.00	0.00
Cash generated from operations	3.03	3.56
Direct Taxes Paid	65.02	(299.53)
Net Cash from operating activities (A)	(367.89)	(655.45)
	-	(43.01)
Cash flows from Investing Activities	(367.89)	(698.46)
Purchase of Fixed Assets (Including CWIP)		
Intangible Assets		
Net Cash used in Investing Activities	(72.34)	(44.00)
	0.00	0.00
Cash flows from/(used in) Financing Activities	(72.34)	(44.00)
Issue of Share Capital Issue of		
Share Warrants		
Proceeds from Long term borrowings Repayment/Proceeds	-	1,438.70
of/from Short-term borrowings Interest paid	307.51	(479.92)
Net Cash used in Financing Activities	(11.93)	(55.32)
	121.68	(0.72)
Net Increase/(Decrease) in cash and cash equivalents	(37.09)	(96.40)
	380.17	806.35
Cash and Cash equivalents at the beginning of the year		
Cash and Cash equivalents at the ending of the year	(60.06)	63.89
	73.33	9.44
	13.26	73.33

For Vista Pharmaceuticals Limited

Dhananjay



Date: 13.11.2025
Place: Hyderabad

Dhananjay Alli
Whole Time Director
DIN: 00610909

:

Independent Auditor's Review Report on unaudited Quarterly Financial results of VISTA PHARMACEUTICALS LIMITED Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To,
The Board of Directors,
Vista Pharmaceuticals Limited.

1. We have reviewed the accompanying statement of unaudited financial results of Vista Pharmaceuticals Limited ("the Company") for the quarter ended and Six months ended September 30, 2025 ("the Statement") attached herewith, being submitted by the company Pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Regulation")
2. This Statement, which is the responsibility of the company's Management and approved by the Board of Directors, has been Prepared in accordance with the recognition and measurement principles laid down in Ind AS 34 "Interim Financial Reporting", prescribed under Section 133 of the companies act, 2013 read with relevant rules issued there under and other recognised accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We Conducted our review of the statement in accordance with the Standard of Review engagement (SRE) 2410, "Review of Interim Financial Information Performed by the independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether financial results are free of material misstatements. A review Consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly we do not express an audit Opinion.

4. Based on our review conducted and Procedures performed as stated in Paragraph 3 as above, nothing has come to our attention that causes us to believe that the accompanying Statement of unaudited Financial results prepared in accordance with the recognition and measurement principles laid down in IND AS 34, Prescribed under Section 133 of the Companies act, 2013 read with relevant rules issued thereunder and other recognized accounting principles generally accepted in India has not disclosed the information required to be disclosed in terms of the regulation including the manner in which it is to be disclosed, or that it contains any material misstatement.

For A.M REDDY & D.R REDDY

Chartered Accountants

Firms Registration No : 0090685



D.Rama Krishna Reddy

Partner

Membership No. 209211

UDIN: 25209211BMJBQU2508

Place: Hyderabad

Date: November 13, 2025

